home / stock / huge:cc / huge:cc news

HUGE:CC News and Press, Fsd Pharma Inc. Subordinate Voting Shares From 04/17/24

Stock Information
Company Name: Fsd Pharma Inc. Subordinate Voting Shares
Stock Symbol: HUGE:CC
Market: CNQC
Website: fsdpharma.com
Menu
HUGE:CC HUGE:CC Quote HUGE:CC Short HUGE:CC News HUGE:CC Articles HUGE:CC Message Board
Get HUGE:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
HUGE:CC - FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products

TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announce...
HUGE:CC - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is reporting on its investment in Celly Nutrition Corp. According to the report, FSA enter...

HUGE:CC - FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption

TORONTO, ON / ACCESSWIRE / April 15, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alc...

HUGE:CC - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Files Q4, Year-End 2023 Financial Results

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has filed its audited annual financial results. According to the announcement, the results...
HUGE:CC - FSD Pharma Announces Filing of Year-End 2023 Results

TORONTO, ON / ACCESSWIRE / April 1, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today a...

HUGE:CC - Expected Canadian Company Earnings on Friday, March 29th, 2024

Multi-Metal Development Ltd. (MLY:CA) is expected to report for quarter end 2023-12-31 Marimaca Copper Corp. (MARI:CA) is expected to report for Q4 2023 Fury Gold Mines Limited (FURY:CA) is expected to report for Q4 2023 Titan Medical Inc. (TMD:CA) is expected to report for quarter en...

HUGE:CC - News Alert: FSD Pharma - FDA Approval to Submit I.N.D. Application for Compound to Treat Covid-19 Patients

2024-03-27 17:08:02 ET The FDA approved FSD Pharma to submit an Investigational New Drug (I.N.D.) application FSD Pharma is a specialty biotech pharmaceutical company. FSD Pharma BioSciences, Inc., is a wholly-owned subsidiary. Moreover, it is a specialty biotech pharmaceutical R&...
HUGE:CC - FSD Pharma: Developing its PEA Compound to Treat COVID-19

2024-03-27 17:08:02 ET Drug with properties to reduce chronic inflammation FSD Pharma is a specialty biotech pharmaceutical R&D company. FSD Pharma BioSciences, a wholly-owned subsidiary, is focusing on developing multiple applications of the company’s lead compound FSD...

HUGE:CC - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, through its subsidiary, HUGE Biopharma Australia Pty Ltd., entered into agreement with iNG...

HUGE:CC - FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults

TORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today anno...
Previous 10 Next 10